Please Wait...

Sean Stanton

Main profile

Sean Stanton
Senior Vice President Global Operations, Research Network

Sean is a senior life science executive who has dedicated the last 25 years of his career to creating successful, high-performing research sites. To date, Sean has led the start-up of 25 clinical trial sites, six inpatient hospitals, and 19 outpatient clinics. More than 5,000 clinical trials have been conducted at these sites, leading to more than 50 drug approvals. Prozac was the first approved drug Sean worked on, followed by many other well-known drugs used in a variety of therapeutic areas (e.g., General Medicine, Vaccine, Women’s Health, Diabetes; Pain; Mental Health; Heart Disease; Oncology; Neurodegenerative Diseases; Sleep Disorders; etc.). In these trials Sean directed recruitment for the screening of 2,000 to 6,000 patients annually. A pioneer in patient recruitment, Sean was the first to pre-screen for screens and was on the forefront of direct-to consumer advertising, circa 1997.

Sean has brought innovative thinking to clinical research in all aspects of site practices, from purchasing and resourcing, to the use of benchmarking and metrics in business planning to guide strategic clinical trial practice growth. Sean is frequently sought as an industry expert to speak on topics including building successful clinical research sites; patient recruiting, particularly difficult to recruit populations and decreasing screen fail rates; protocol design; site selection; patient reported outcomes and other areas. He has advised hospitals and institutions on research site growth strategy and mergers and acquisitions at the site level.

Sean is the co-founder of the highly successful Compass Research, a leading Florida-based site network, since acquired and successfully integrated in Bioclinica Research Network. At Bioclinica, Sean is responsible for a global site network in 14 countries on four continents. Early in his career Sean held numerous pre-clinical and clinical research positions in neuroscience. He began his career as a clinical research coordinator at the University of Cincinnati Medical Center, Department of Psychiatry. Sean has a bachelor’s degree in Biology from the University of Cincinnati.

Blogs

Nobody wants a delay in site activation for a clinical trial. Every delay increases study budgets and reduces the time for market exclusivity. A delay means patients aren't getting needed drugs. Yet delays happen – consistently. So what is the secret to swift site activation? What is the "special sauce" to speed up the process and get studies started on time?

You have a new drug awaiting clinical trial, but your site activation process is stuck in the mud. Every day that passes is another delay in finding the patients you need. Getting the data you want. Generating the revenue you require. So why is site activation such a slow slog?

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

What's next from Bioclinica? Hear if first during #PCTrials Europe next week in Amsterdam! https://t.co/ICngaxA9mg https://t.co/SXxPj3NpD2
bioclinica (5 hours ago)
Join Bioclinica's Justin Hunt on Nov. 28 in a live webinar! Find out how to overcome common hurdles in CTMS impleme… https://t.co/wHfWHtI7sj
bioclinica (Yesterday)
Another CRO seeing big gains in the sites payments process! Access the Case Study here https://t.co/jsCxhmKcLo https://t.co/LpIKEtBKtE
bioclinica (Yesterday)
Great advice from our Dir. Cardiovascular Imaging on quality imaging acquisitions & assessments in clin trials. https://t.co/OVH7pZ3SL0
bioclinica (Yesterday)
Almost here! #PCTrials Pre-arrange a meeting w @bioclinica Drop by & s/w David Kiger & Mike Lange. Mike will give a… https://t.co/8ymd2Q9KcJ
bioclinica (Yesterday)
Almost here! #PCTrials Pre-arrange a meeting w @bioclinica Drop by & s/w David Kiger & Mike Lange. Mike will giv… https://t.co/MpxTDV1T1L
bioclinica (Yesterday)

Latest Blogs:

Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen
Congressman Meehan and Bioclinica CEO John Hubbard at recent visit to Bioclinica's Audubon offices